Drugs / HB002.1T
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04802980 | Apr 2020 → Jul 2023 | neoplasm | Huabo Biopharm Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03636750 | Jun 2018 → Feb 2020 | neoplasm | Huabo Biopharm Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB002.1T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03636750 ↗ |
| Modality | Protein / enzyme biologic | “HB002.1T, a human immunoglobulin Fc fusion protein containing domain 2 and flanking sequence of vascular endothelial growth factor (VEGF) receptor-1” NCT03636750 ↗ |
| Route | Intravenous | “via intravenous injection” NCT03636750 ↗ |